SlideShare a Scribd company logo

Atorvastatin:  Statins in CVD management. Is just lipid lowering enough

This document discusses the benefits of statin drugs beyond their lipid-lowering effects. It summarizes several key studies that show statins reduce cardiovascular events in patients with diabetes or chronic kidney disease, even when baseline lipid levels are normal. The document highlights that atorvastatin and simvastatin have evidence from primary prevention trials of reducing cardiovascular outcomes in diabetes, whereas other statins do not. It also notes that atorvastatin seems to have greater renoprotective effects compared to rosuvastatin in diabetes patients with kidney disease and proteinuria.

1 of 37
Download to read offline
Statins in CVD management : Is just
lipid lowering enough?
Dr Vivek Baliga
Consultant Internal Medicine
Director, HeartSenseTM
www.heartsense.in
Preamble
• Statins were originally introduced as lipid lowering drugs, but
today they are recommended in many high risk patient groups
irrespective of baseline lipid levels.
• This suggests that benefits of statins are beyond and
independent of lipid lowering effects.
• So Choice of statin should be based on evidence of CV
benefits rather than lipid lowering
Primary Prevention of CVD
• As per AHA 2013, guidelines all T2DM patients of age 40-75
require either moderate or high dose statin therapy
2016 ADA guidelines for statins in DM
Diabetes Care 2016;39(supple 1): S1-S112
All DM patients with> 1 CV risk factor require
moderate to high dose statin
But what is the evidence that statins reduce CV
events in T2DM patients without high LDL-C?
MI Risk in Diabetics Without Prior MI Equivalent to
Nondiabetic With MI
Haffner SM et al. N Engl J Med. 1998;339:229-234.
Numbers in bars represent number of persons in category at baseline.
Finnish population study (7-year follow-up)
3.5
20.218.8
45
0
10
20
30
40
50
60
Patients without diabetes Patients with diabetes
Incidenceoffatal/nonfatalMI
during7-yearfollow-up(%)
No prior MI
Prior MI
P<0.001
P<0.001
P<0.001 for diabetes vs no diabetes
8901304
69 169
Diabetes is CHD equivalent
RM Parikh et al. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 4 (2010) 10–12
85.5%
Dyslipidemia
97.8 %
Dyslipidemia
85.5 %
Prevalence of Dyslipidemia (%) in
Male T2 DM
Prevalence of Dyslipidemia (%)
in Female T2DM
In India, 90% diabetics have dyslipidemia
Study Patients Follow up Results
ASCOT LLA * 2532 Atorvastatin 10
mg
3.3 yrs 23% risk reduction
CARDS 2838 Atorvastatin 10
mg
3.9 yrs 37% risk reduction
HPS * 2912 Simvastatin 40
mg
5 yrs 33% risk reduction
Major Statin Primary Prevention Trials In
DM
* sub-analysis
Only Atorvastatin and Simvastatin have evidence
that statin reduce CV events in Primary prevention.
OTHERS DO NOT HAVE SUCH EVIDENCE!
4-year follow-up
CARDS: primary prevention in T2DM
Atorvastatin 10 mg/day
(n=1428)
Placebo
(n=1410)
2838 patients
Primary end point:
 Incidence of major cardiovascular events:
– Cardiovascular-related death
– Nonfatal MI
– Stroke
– Resuscitated cardiac arrest
– Unstable angina
– Coronary revascularization procedures
Patient population:
 Age: 40-75 years
 LDL-C 160 mg/dL
 Triglycerides 600 mg/dL
 Type 2 diabetes
 No prior MI or CHD
 1+ CHD risk factor
C o l h o u n H M e t a l . L a n c e t . 2 0 0 4 ; 3 6 4 : 6 8 5 - 6 9 6 .
CARDS: Collaborative Atorvastatin Diabetes Study
At Baseline,
LDL-C: 120 mg/dl
HDL-C: 54.5 mg/dl
Non-HDL-C: 153 mg/dl
CARDS: Atorvastatin reduces CV events by
37%
*Acute CHD event, coronary revascularization, stroke.
RRR: Relative risk reduction
Colhoun HM et al. Lancet. 2004;364:685-696.
0
5
10
15
0 1 2 3 4 5 6
RRR=37% p=0.001
Cumulativeincidence
ofevents(%ofpatients)
127 events
83 events
Time (years)
Atorvastatin 10 mg (n=1428)
Placebo (n=1410)
median follow-up 3.9 years
0
1
2
3
4
5
6
0 1 2 3 4 5 6
CARDS: Atorvastatin Reduces Stroke by
48% in T2DM
Newman C et al. American Heart Association 78th Scientific Sessions, 2005.
RRR= 48% (95% CI: 31%-89%)
P=0.016
Cumulativeincidence
ofevents(%ofpatients)
39 events
21 events
Time (years)
Atorvastatin 10 mg (n=1428)
Placebo (n=1410)
Median follow-up 3.9 years
Stroke was a component of the primary endpoint,
evaluated individually as a secondary survival
analysis.
AHA and ADA guidelines for statin therapy in
T2DM for primary prevention are based on
Atorvastatin’s CARDS trial
Atorvastatin for Primary Prevention in High
risk patients: ASCOT-LLA
A double-blind, placebo-controlled trial of atorvastatin 10 mg Vs
Placebo in 10305 hypertensive patients studied
Median follow up: 3.3 years
Study end points
Primary: Combined nonfatal MI (including silent MI) and fatal CHD
Secondary: Fatal and nonfatal stroke
Total cardiovascular events and procedures
Total coronary events
Atorvastatin 10 mg Number of events 89
Placebo Number of events 121
0
1
2
3
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Years
CumulativeIncidence(%)
HR = 0.73 (0.56-0.96)
P = .0236
27%
reduction
ASCOT-LLA
Primary Endpoint:
Nonfatal MI and Fatal CHD
Secondary Endpoint:
Fatal and Nonfatal Stroke
0
1
2
3
4
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Years
CumulativeIncidence(%)
Atorvastatin 10 mg Number of events 100
Placebo Number of events 154
36%
reduction
HR = 0.64 (0.50-0.83)
P = .0005
Sever PS, et al. Lancet. 2003;361:1149-1158.
ASCOT-LLA: Primary prevention– DM Sub-
analysis (yellow cells)
Highlighted boxes indicate diabetes patients enrolled in lipid-lowering arm.
-blocker ± diuretic CCB ± ACE inhibitor
TC >250 mg/dL
(>6.5 mmol/L)
2532 TC 250 mg/dL
(6.5 mmol/L)
TC >250 mg/dL
(>6.5 mmol/L)
Open lipid lowering
1258
Atorvastatin 10 mg
1274
Placebo
Open lipid lowering
19,342 patients
Randomized
Randomized
Primary end point: Composite of fatal CHD and nonfatal MI
ASCOT: LLA: Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm
Sever PS et al. J Hypertens. 2001;19:1139-1147. CCB: Calcium Channel Blocker
ACE: Angiotension Convertase Inhibitor TC: Total Cholesterol
ASCOT-LLA :23% RRR for total CV events in DM
patients with atorvastatin
Sever PS et al. Diabetes Care. 2005;28:1151-1157.
0
5
10
15
0 1 2 3 4 5 6
RRR=23%
P=0.036
151 events
116 events
median follow-up 3.3 years
Cumulativeincidence
ofevents(%ofpatients)
Time (years)
Atorvastatin 10 mg
Placebo
Statin in CKD patients
Alterations in Lipid Profiles in CKD
Clin J Am Soc Nephrol 2007; 2(4):766-85.
Triglycerides
HDL
Lipoprotein (a)
Normal or low LDL
Normal or low TC
VLDL remnants
Dose of statins in patients with CKD
• Atorvastatin: No dose adjustment required
• Rosuvastatin: In patients severe CKD with creatinine
clearance < 30 ml/min (not on hemodialysis), Maximum dose:
10 mg/day
• Pitavastatin: in patients with moderate/severe CKD (GFR:
15-59 ml/min) Maximum dose: 2 mg/day,
GFR: Glomerular Filtration Rate
• Patients: 325 DM nephropathy patients urinary protein/creatinine ratios
(UPCR): 500-5000 mg/g, LDL >90 mg/dL, and on ACEIs/ARBs for > 3
months.
• Patients divided in 3 groups: Rosuvastatin 10 mg, Rosuvastatin 40 mg and
Atorvastatin 80 mg for duration of 52 weeks
• Baseline eGFR: 69-72 ml/min Baseline UPCR: 1160-1260 mg/g
• The primary end point: Change in urinary protein/ creatinine ratio
from baseline to week 52
Atorvastatin vs Rosuvastatin in DM+ CKD
PLANET I study
The Lancet Diabetes & Endocrinology 2015;3(3):181-90
PLANET I: % Change in UPCR and eGFR
-13
2
-4
-14
-12
-10
-8
-6
-4
-2
0
2
4
UPCR Change (%)
Atorvastatin 80 mg
Rosuvastatin 10 mg
Rosuvastatin 40 mg
p=0.033
p=0.83
p=0.53
The Lancet Diabetes & Endocrinology 2015;3(3):181-90
-1.61
-3.7
-7.29
-8
-7
-6
-5
-4
-3
-2
-1
0
Change in eGFR
Atorvastatin 80 mg
Rosuvastatin 10 mg
Rosuvastatin 40 mg
Conclusion: Atorvastatin seems to have more renoprotective
effects for the studied chronic kidney disease population.
de Zeeuw D. 2010European Renal Association-European Dialysis and Transplant Association Congress; June 27,
2010; Munich, Germany.
Atorvastatin vs Rosuvastatin for
renal function PLANET I:
Adverse event
Rosuvastatin
10 mg/day
(n = 116)
Rosuvastatin
40 mg/day
(n = 123)
Atorvastatin
80 mg/day
(n = 110) p
Any renal
adverse event
7.8 9.8 4.5 NS
Acute renal failure 0.0 4.1 0.9 <0.05
Serum creatinine
doubling
0.0 4.9 0.0 <0.01
Serum creatinine
doubling or acute
renal failure
0.0 7.3 0.9 <0.01
• A meta-analysis of 5 clinical trials head to
head comparing atorvastatin vs rosuvastatin
Atorvastatin Vs Rosuvastatin For Proteinuria: A
Meta-analysis
Circ J 2012;76:1259-66
Atorvastatin is safer than Rosuvastatin in DM
patients with proteinuria
Atorvastatin is better than Rosuvastatin for
reduction in proteinuria
2013 KDIGO Guidelines for dyslipidemia
management in CKD
• In adults aged > 50 years with eGFR< 60 ml/min/1.73
m2 but not treated with chronic dialysis or kidney
transplantation (GFR categories G3a-G5), we
recommend treatment with a statin or
statin/ezetimibe combination. (1A)
• In adults aged > 50 years with CKD and eGFR> 60
ml/min/1.73m2 (GFR categories G1-G2) we
recommend treatment with a statin. (1B)
Rosuvastatin 20 mg (N=8901) MI
Stroke
Unstable
Angina
CVD Death
CABG/PTCA
4-week
run-in
Ridker PM et al, Circulation 2003;108:2292-2297
No Prior
CVD/CKD/DM
Men >50, Women >60
LDL <130 mg/dL
hsCRP >2 mg/L
Placebo (N=8901)
Follow up: 1.9 yrs
Can we consider rosuvastatin for primary
prevention in DM/CKD based on JUPITER?
Patients with DM and CKD were excluded from
JUPITER, So there is no evidence for primary CV
prevention with rosuvastatin in DM/CKD!!!
Statin for secondary prevention
• Current guidelines recommend moderate to high dose of
statins for secondary prevention.
• Atorvastatin has multiple landmark trials for secondary
prevention
771 pts with
NSTE-ACS
sent to
early coronary
angiography
(<48 hours)
Randomization(N=191)
Atorvastatin 80 mg
12 hrs pre-angio;
further 40 mg
2 hrs before
N=96
Coronary
angiography
Placebo
12 hrs pre-angio;
further
dose 2 hrs
before
N=95
Primary end
point:
30-day
death, MI,
TVR
1st blood sample
(pre-PCI)
CK-MB, troponin-I, myoglobin, CRP
High dose Atorvastatin in ACS
ARMYDA-ACS trial
2nd and 3rd
blood samples
(8 and 24 hrs
post-PCI)
30 days
580 pts excluded for:
- 451 statin therapy
- 41 emergency angiography
- 43 LVEF <30%
- 30 contraindications to statins
- 15 severe renal failure
PCI
atorvastatin
N=86
PCI
placebo
N=85
20 pts excluded for indication to:
- medical therapy (N=8)
- bypass surgery (N=12)
atorvast
ARMYDA-ACS: Secondary end point
Post-PCI percent increase of CRP levels from baseline
%
63
147
P=0.01
JACC 2007:49:1272-78
ARMYDA-ACS trial
Composite primary end-point (30-day death, MI, TVR)
%
5
17
P=0.01
JACC 2007:49:1272-78
• 383 patients with stable angina (53%) or NST-ACS (47%)
and on chronic statin therapy (55% atorvastatin)
undergoing PCI were randomized to atorvastatin reload
(80 mg 12 h before intervention, 40-mg pre-procedural
dose or placebo (n=191).
• All patients received long-term atorvastatin treatment
thereafter (40 mg/day).
• The primary end point was 30-day incidence of major
adverse cardiac events (cardiac death, myocardial
infarction, or unplanned revascularization).
Loading atorvastatin in patients already
on statin ARMYDA-RECAPTURE
J. Am. Coll. Cardiol. 2009;54;558-565
ARMYDA-RECAPTURE:
PRIMARY ENDPOINT
0
3
6
9
12
3.4
9.1
P=0.045
PlaceboAtorvastatin
Loading of Atorvastatin high dose before
PCI can reduce the CV events
J. Am. Coll. Cardiol. 2009;54;558-565
Atorvastatin 80 mg
n=4,995
Primary Endpoint: Major cardiovascular event defined as coronary
heart death (CHD), nonfatal M, resuscitated cardiac arrest, and fatal or
nonfatal stroke at a mean follow-up of 4.9 years.
Atorvastatin for stable CAD
TNT Trial
Presented at ACC 2005
Atorvastatin 10 mg
n=5,006
10,003 patients with stable coronary heart disease
Age 35-75 years, LDL between 130 and 250 mg/dL, triglyceride ≤ 600 mg/dL
19% female, mean age 60.3 years
All received atorvastatin 10 mg during 8 week open-label run-in period
TNT Trial: Primary endpoint
Hazard Ratio [HR]=0.78
p<0.001
Presented at ACC 2005
4,162 patients with an Acute Coronary Syndrome < 10 days
ASA + Standard Medical Therapy
“Standard Therapy”
Pravastatin 40 mg
“Intensive Therapy”
Atorvastatin 80 mg
Duration: Mean 2 year follow-up (>925 events)
Atorvastatin in ACS: PROVE IT - TIMI 22
2x2 Factorial: Gatifloxacin vs. placebo
Double-blind
Primary Endpoint: Death, MI, Documented UA requiring hospitalization,
revascularization (> 30 days after randomization), or Stroke
CV events in PROVE IT study
Cannon et al. NEJM 2004 Ray et al. Am J Cardiol 2006
Death/MACEDeath/MI/Urg. Revascu.
↓33%
↓16%
Intensive statin therapy provides more benefits than
low/moderate Intensity statin
Take Home Message
• CV protection with statin is not completely dependent on
lipid lowering.
• Though rosuvastatin is slightly more effective than
atorvastatin for lipid lowering, Atorvastatin has stronger
evidence for CV protection
• Atorvastatin is approved in both primary and secondary
prevention, while rosuvastatin is approved only in
primary prevention in patients with hsCRP > 2 mg/L
WITHOUT DM/CKD

Recommended

Crestor Presentation
Crestor PresentationCrestor Presentation
Crestor Presentationhospital
 
Management of dyslipidemia 2019 update
Management of dyslipidemia  2019 update Management of dyslipidemia  2019 update
Management of dyslipidemia 2019 update Moustafa Mokarrab
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“Arindam Pande
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDr Vivek Baliga
 

More Related Content

What's hot

Dyslipidemia guidelines
Dyslipidemia guidelinesDyslipidemia guidelines
Dyslipidemia guidelinesAinshamsCardio
 
Lipid lowering trials ppt
Lipid lowering trials pptLipid lowering trials ppt
Lipid lowering trials pptNavin Agrawal
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemiaRajesh Rayidi
 
LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”Arindam Pande
 
2023 AHAACC Guideline.pptx
2023 AHAACC Guideline.pptx2023 AHAACC Guideline.pptx
2023 AHAACC Guideline.pptxAadhi55
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...MedicineAndFamily
 
PCSK9 Inhibitors PP
PCSK9 Inhibitors PPPCSK9 Inhibitors PP
PCSK9 Inhibitors PPVince Netto
 
SGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes managementSGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes managementPraveen Nagula
 
DYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINESDYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINESarnab ghosh
 
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment optionsSGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment optionsahvc0858
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...magdy elmasry
 
Antiplatelet therapy
Antiplatelet therapyAntiplatelet therapy
Antiplatelet therapyArindam Pande
 

What's hot (20)

Dyslipidemia guidelines
Dyslipidemia guidelinesDyslipidemia guidelines
Dyslipidemia guidelines
 
Rosuvastatin
RosuvastatinRosuvastatin
Rosuvastatin
 
2019 ESC/EAS Guidelines on Dyslipidaemias
2019 ESC/EAS Guidelines on Dyslipidaemias2019 ESC/EAS Guidelines on Dyslipidaemias
2019 ESC/EAS Guidelines on Dyslipidaemias
 
Lipid lowering trials ppt
Lipid lowering trials pptLipid lowering trials ppt
Lipid lowering trials ppt
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemia
 
Dyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to HeadDyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to Head
 
LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”
 
2023 AHAACC Guideline.pptx
2023 AHAACC Guideline.pptx2023 AHAACC Guideline.pptx
2023 AHAACC Guideline.pptx
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
 
SGLT2 inhibitors
SGLT2 inhibitorsSGLT2 inhibitors
SGLT2 inhibitors
 
PCSK9 Inhibitors PP
PCSK9 Inhibitors PPPCSK9 Inhibitors PP
PCSK9 Inhibitors PP
 
Statin combinations
Statin combinationsStatin combinations
Statin combinations
 
SGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes managementSGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes management
 
DYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINESDYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINES
 
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment optionsSGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
 
Arni
ArniArni
Arni
 
Ticagrelor
TicagrelorTicagrelor
Ticagrelor
 
dyslipidemia6.ppt
dyslipidemia6.pptdyslipidemia6.ppt
dyslipidemia6.ppt
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
 
Antiplatelet therapy
Antiplatelet therapyAntiplatelet therapy
Antiplatelet therapy
 

Viewers also liked

Role of atorvastatin
Role of atorvastatinRole of atorvastatin
Role of atorvastatinvelspharmd
 
Atorvastatin
AtorvastatinAtorvastatin
Atorvastatinkenny_gwc
 
Towards Methods for Efficient Access to Spoken Content in the AMI Corpus (SSC...
Towards Methods for Efficient Access to Spoken Content in the AMI Corpus (SSC...Towards Methods for Efficient Access to Spoken Content in the AMI Corpus (SSC...
Towards Methods for Efficient Access to Spoken Content in the AMI Corpus (SSC...Maria Eskevich
 
Fhd cvd risk reduction presentation 08232016 final
Fhd cvd risk reduction presentation 08232016 finalFhd cvd risk reduction presentation 08232016 final
Fhd cvd risk reduction presentation 08232016 finalholtzal
 
Center Scope Fall 2014
Center Scope Fall 2014Center Scope Fall 2014
Center Scope Fall 2014Marilyn Mann
 
Analysis of Global Atorvastatin Calcium Production, Supply, Sales and Market ...
Analysis of Global Atorvastatin Calcium Production, Supply, Sales and Market ...Analysis of Global Atorvastatin Calcium Production, Supply, Sales and Market ...
Analysis of Global Atorvastatin Calcium Production, Supply, Sales and Market ...Pallavi Pawar
 
Physicochemical characterization of drugs
Physicochemical characterization of drugs Physicochemical characterization of drugs
Physicochemical characterization of drugs Sagar Savale
 
Dyslipidemia & ayurveda
Dyslipidemia & ayurvedaDyslipidemia & ayurveda
Dyslipidemia & ayurvedaAmit Sharma
 
Atorvastatin & dyslipidemia
Atorvastatin & dyslipidemiaAtorvastatin & dyslipidemia
Atorvastatin & dyslipidemiaMUPEG
 
SXSW2013: Design for Aging, Your Future-Self
SXSW2013: Design for Aging, Your Future-SelfSXSW2013: Design for Aging, Your Future-Self
SXSW2013: Design for Aging, Your Future-SelfCarina Ngai
 

Viewers also liked (20)

Atorvastatin
AtorvastatinAtorvastatin
Atorvastatin
 
Role of atorvastatin
Role of atorvastatinRole of atorvastatin
Role of atorvastatin
 
Atorvastatin
AtorvastatinAtorvastatin
Atorvastatin
 
Statin
StatinStatin
Statin
 
Statins
StatinsStatins
Statins
 
Statin Wars
Statin WarsStatin Wars
Statin Wars
 
Towards Methods for Efficient Access to Spoken Content in the AMI Corpus (SSC...
Towards Methods for Efficient Access to Spoken Content in the AMI Corpus (SSC...Towards Methods for Efficient Access to Spoken Content in the AMI Corpus (SSC...
Towards Methods for Efficient Access to Spoken Content in the AMI Corpus (SSC...
 
Fhd cvd risk reduction presentation 08232016 final
Fhd cvd risk reduction presentation 08232016 finalFhd cvd risk reduction presentation 08232016 final
Fhd cvd risk reduction presentation 08232016 final
 
Improve it slides
Improve it slidesImprove it slides
Improve it slides
 
Center Scope Fall 2014
Center Scope Fall 2014Center Scope Fall 2014
Center Scope Fall 2014
 
M.PHARM_ Rupsa Ghosh
M.PHARM_ Rupsa GhoshM.PHARM_ Rupsa Ghosh
M.PHARM_ Rupsa Ghosh
 
Analysis of Global Atorvastatin Calcium Production, Supply, Sales and Market ...
Analysis of Global Atorvastatin Calcium Production, Supply, Sales and Market ...Analysis of Global Atorvastatin Calcium Production, Supply, Sales and Market ...
Analysis of Global Atorvastatin Calcium Production, Supply, Sales and Market ...
 
ROSUVASTATIN CALCIUM PPT
ROSUVASTATIN CALCIUM PPTROSUVASTATIN CALCIUM PPT
ROSUVASTATIN CALCIUM PPT
 
Physicochemical characterization of drugs
Physicochemical characterization of drugs Physicochemical characterization of drugs
Physicochemical characterization of drugs
 
Dyslipidemia & ayurveda
Dyslipidemia & ayurvedaDyslipidemia & ayurveda
Dyslipidemia & ayurveda
 
Lipitor
LipitorLipitor
Lipitor
 
Pfizer lipitor
Pfizer   lipitorPfizer   lipitor
Pfizer lipitor
 
Atorvastatin & dyslipidemia
Atorvastatin & dyslipidemiaAtorvastatin & dyslipidemia
Atorvastatin & dyslipidemia
 
Myocarditis
MyocarditisMyocarditis
Myocarditis
 
SXSW2013: Design for Aging, Your Future-Self
SXSW2013: Design for Aging, Your Future-SelfSXSW2013: Design for Aging, Your Future-Self
SXSW2013: Design for Aging, Your Future-Self
 

Similar to Atorvastatin:  Statins in CVD management. Is just lipid lowering enough

Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?Dr Vivek Baliga
 
Mubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD | Effects of statin or usual care on outcomesMubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD | Effects of statin or usual care on outcomesMubashar A Choudry MD
 
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...Sociedad Española de Cardiología
 
Abordaje terapéutico de la dislipemia en el paciente con enfermedad renal cró...
Abordaje terapéutico de la dislipemia en el paciente con enfermedad renal cró...Abordaje terapéutico de la dislipemia en el paciente con enfermedad renal cró...
Abordaje terapéutico de la dislipemia en el paciente con enfermedad renal cró...Sociedad Española de Cardiología
 
Evolocumab Amgan sept 2020.Dr adel sallam.pptx
Evolocumab  Amgan sept 2020.Dr adel sallam.pptxEvolocumab  Amgan sept 2020.Dr adel sallam.pptx
Evolocumab Amgan sept 2020.Dr adel sallam.pptxAdelSALLAM4
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDr Vivek Baliga
 
Managing Diabetic Thrombocytopathy: Focussing on OAPS
Managing Diabetic Thrombocytopathy:   Focussing on OAPSManaging Diabetic Thrombocytopathy:   Focussing on OAPS
Managing Diabetic Thrombocytopathy: Focussing on OAPSsrisrihoistic hospital
 
Atorwin rtd 2014 dr sukartono
Atorwin   rtd 2014 dr sukartonoAtorwin   rtd 2014 dr sukartono
Atorwin rtd 2014 dr sukartonoFamiliantoro Maun
 
2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol managementPraveen Nagula
 
14.09 bp management in diabetes
14.09 bp management in diabetes14.09 bp management in diabetes
14.09 bp management in diabetesRajeev Agarwala
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...SYEDRAZA56411
 
Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fib...
Novel Oral Anticoagulants  for Stroke Prevention in  Patients With Atrial Fib...Novel Oral Anticoagulants  for Stroke Prevention in  Patients With Atrial Fib...
Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fib...Choying Chen
 
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...rdaragnez
 

Similar to Atorvastatin:  Statins in CVD management. Is just lipid lowering enough (20)

Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
Dyslipidemia 2016
 
Mubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD | Effects of statin or usual care on outcomesMubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD | Effects of statin or usual care on outcomes
 
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
 
Abordaje terapéutico de la dislipemia en el paciente con enfermedad renal cró...
Abordaje terapéutico de la dislipemia en el paciente con enfermedad renal cró...Abordaje terapéutico de la dislipemia en el paciente con enfermedad renal cró...
Abordaje terapéutico de la dislipemia en el paciente con enfermedad renal cró...
 
Evolocumab Amgan sept 2020.Dr adel sallam.pptx
Evolocumab  Amgan sept 2020.Dr adel sallam.pptxEvolocumab  Amgan sept 2020.Dr adel sallam.pptx
Evolocumab Amgan sept 2020.Dr adel sallam.pptx
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approach
 
SGLT2 inhibitor trials
SGLT2 inhibitor trialsSGLT2 inhibitor trials
SGLT2 inhibitor trials
 
Managing Diabetic Thrombocytopathy: Focussing on OAPS
Managing Diabetic Thrombocytopathy:   Focussing on OAPSManaging Diabetic Thrombocytopathy:   Focussing on OAPS
Managing Diabetic Thrombocytopathy: Focussing on OAPS
 
Atorwin rtd 2014 dr sukartono
Atorwin   rtd 2014 dr sukartonoAtorwin   rtd 2014 dr sukartono
Atorwin rtd 2014 dr sukartono
 
2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management
 
14.09 bp management in diabetes
14.09 bp management in diabetes14.09 bp management in diabetes
14.09 bp management in diabetes
 
Diabetic Dyslipidemia Slide Share
Diabetic  Dyslipidemia Slide ShareDiabetic  Dyslipidemia Slide Share
Diabetic Dyslipidemia Slide Share
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
 
Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fib...
Novel Oral Anticoagulants  for Stroke Prevention in  Patients With Atrial Fib...Novel Oral Anticoagulants  for Stroke Prevention in  Patients With Atrial Fib...
Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fib...
 
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
 
Lipid lowering after an Acute Coronary Syndrome -strategies for success
Lipid lowering after an Acute Coronary Syndrome -strategies for successLipid lowering after an Acute Coronary Syndrome -strategies for success
Lipid lowering after an Acute Coronary Syndrome -strategies for success
 
Statins
StatinsStatins
Statins
 
Dkd new look
Dkd new lookDkd new look
Dkd new look
 
Osborn - Lipids 2019 cholesterol guidelines
Osborn - Lipids 2019 cholesterol guidelinesOsborn - Lipids 2019 cholesterol guidelines
Osborn - Lipids 2019 cholesterol guidelines
 

More from Dr Vivek Baliga

LA Myxoma - For Medical Students
LA Myxoma - For Medical StudentsLA Myxoma - For Medical Students
LA Myxoma - For Medical StudentsDr Vivek Baliga
 
White Coat Hypertension - Dr Vivek Baliga Patient Presentation
White Coat Hypertension - Dr Vivek Baliga Patient PresentationWhite Coat Hypertension - Dr Vivek Baliga Patient Presentation
White Coat Hypertension - Dr Vivek Baliga Patient PresentationDr Vivek Baliga
 
Stomach Bloating And Acidity - Tips To Rid Yourself Of It - Dr Vivek Baliga P...
Stomach Bloating And Acidity - Tips To Rid Yourself Of It - Dr Vivek Baliga P...Stomach Bloating And Acidity - Tips To Rid Yourself Of It - Dr Vivek Baliga P...
Stomach Bloating And Acidity - Tips To Rid Yourself Of It - Dr Vivek Baliga P...Dr Vivek Baliga
 
Lower blood pressure without medicines - Dr Vivek Baliga Patient Guide
Lower blood pressure without medicines - Dr Vivek Baliga Patient GuideLower blood pressure without medicines - Dr Vivek Baliga Patient Guide
Lower blood pressure without medicines - Dr Vivek Baliga Patient GuideDr Vivek Baliga
 
Ezetimibe And Lipids - Dr Vivek Baliga Reviews
Ezetimibe And Lipids - Dr Vivek Baliga ReviewsEzetimibe And Lipids - Dr Vivek Baliga Reviews
Ezetimibe And Lipids - Dr Vivek Baliga ReviewsDr Vivek Baliga
 
Frozen shoulder dr vivek baliga review
Frozen shoulder   dr vivek baliga reviewFrozen shoulder   dr vivek baliga review
Frozen shoulder dr vivek baliga reviewDr Vivek Baliga
 
Dr Vivek Baliga Review - Case Of A Rash On The Hips
Dr Vivek Baliga Review - Case Of A Rash On The HipsDr Vivek Baliga Review - Case Of A Rash On The Hips
Dr Vivek Baliga Review - Case Of A Rash On The HipsDr Vivek Baliga
 
Plantar fasciitis - A Simple Patient Guide by Dr Vivek Baliga, Bangalore
Plantar fasciitis - A Simple Patient Guide by Dr Vivek Baliga, BangalorePlantar fasciitis - A Simple Patient Guide by Dr Vivek Baliga, Bangalore
Plantar fasciitis - A Simple Patient Guide by Dr Vivek Baliga, BangaloreDr Vivek Baliga
 
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient PresentationLosing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient PresentationDr Vivek Baliga
 
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationCombination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationDr Vivek Baliga
 
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek BaligaNewer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek BaligaDr Vivek Baliga
 
Heart disease in post menopausal women
Heart disease in post menopausal womenHeart disease in post menopausal women
Heart disease in post menopausal womenDr Vivek Baliga
 
Irritable Bowel Syndrome - Part 2
Irritable Bowel Syndrome - Part 2Irritable Bowel Syndrome - Part 2
Irritable Bowel Syndrome - Part 2Dr Vivek Baliga
 
ECG In Ischemic Heart Disease - Dr Vivek Baliga Review
ECG In Ischemic Heart Disease - Dr Vivek Baliga ReviewECG In Ischemic Heart Disease - Dr Vivek Baliga Review
ECG In Ischemic Heart Disease - Dr Vivek Baliga ReviewDr Vivek Baliga
 
Understanding Enlarged Prostate Glands - Dr Vivek Baliga Patient Presentation
Understanding Enlarged Prostate Glands - Dr Vivek Baliga Patient PresentationUnderstanding Enlarged Prostate Glands - Dr Vivek Baliga Patient Presentation
Understanding Enlarged Prostate Glands - Dr Vivek Baliga Patient PresentationDr Vivek Baliga
 
Irritable Bowel Syndrome Part 1 - Dr Vivek Baliga
Irritable Bowel Syndrome Part 1 - Dr Vivek BaligaIrritable Bowel Syndrome Part 1 - Dr Vivek Baliga
Irritable Bowel Syndrome Part 1 - Dr Vivek BaligaDr Vivek Baliga
 
Post viral pericarditis - Dr Vivek Baliga presentation
Post viral pericarditis - Dr Vivek Baliga presentationPost viral pericarditis - Dr Vivek Baliga presentation
Post viral pericarditis - Dr Vivek Baliga presentationDr Vivek Baliga
 
Dr Vivek Baliga - Diastolic heart failure - A complete overview
Dr Vivek Baliga - Diastolic heart failure - A complete overviewDr Vivek Baliga - Diastolic heart failure - A complete overview
Dr Vivek Baliga - Diastolic heart failure - A complete overviewDr Vivek Baliga
 
Dr Vivek Baliga - Chronic Disease Management In Heart Failure And Diabetes
Dr Vivek Baliga - Chronic Disease Management In Heart Failure And DiabetesDr Vivek Baliga - Chronic Disease Management In Heart Failure And Diabetes
Dr Vivek Baliga - Chronic Disease Management In Heart Failure And DiabetesDr Vivek Baliga
 
Pulmonary embolism - Diagnosis and management
Pulmonary embolism - Diagnosis and managementPulmonary embolism - Diagnosis and management
Pulmonary embolism - Diagnosis and managementDr Vivek Baliga
 

More from Dr Vivek Baliga (20)

LA Myxoma - For Medical Students
LA Myxoma - For Medical StudentsLA Myxoma - For Medical Students
LA Myxoma - For Medical Students
 
White Coat Hypertension - Dr Vivek Baliga Patient Presentation
White Coat Hypertension - Dr Vivek Baliga Patient PresentationWhite Coat Hypertension - Dr Vivek Baliga Patient Presentation
White Coat Hypertension - Dr Vivek Baliga Patient Presentation
 
Stomach Bloating And Acidity - Tips To Rid Yourself Of It - Dr Vivek Baliga P...
Stomach Bloating And Acidity - Tips To Rid Yourself Of It - Dr Vivek Baliga P...Stomach Bloating And Acidity - Tips To Rid Yourself Of It - Dr Vivek Baliga P...
Stomach Bloating And Acidity - Tips To Rid Yourself Of It - Dr Vivek Baliga P...
 
Lower blood pressure without medicines - Dr Vivek Baliga Patient Guide
Lower blood pressure without medicines - Dr Vivek Baliga Patient GuideLower blood pressure without medicines - Dr Vivek Baliga Patient Guide
Lower blood pressure without medicines - Dr Vivek Baliga Patient Guide
 
Ezetimibe And Lipids - Dr Vivek Baliga Reviews
Ezetimibe And Lipids - Dr Vivek Baliga ReviewsEzetimibe And Lipids - Dr Vivek Baliga Reviews
Ezetimibe And Lipids - Dr Vivek Baliga Reviews
 
Frozen shoulder dr vivek baliga review
Frozen shoulder   dr vivek baliga reviewFrozen shoulder   dr vivek baliga review
Frozen shoulder dr vivek baliga review
 
Dr Vivek Baliga Review - Case Of A Rash On The Hips
Dr Vivek Baliga Review - Case Of A Rash On The HipsDr Vivek Baliga Review - Case Of A Rash On The Hips
Dr Vivek Baliga Review - Case Of A Rash On The Hips
 
Plantar fasciitis - A Simple Patient Guide by Dr Vivek Baliga, Bangalore
Plantar fasciitis - A Simple Patient Guide by Dr Vivek Baliga, BangalorePlantar fasciitis - A Simple Patient Guide by Dr Vivek Baliga, Bangalore
Plantar fasciitis - A Simple Patient Guide by Dr Vivek Baliga, Bangalore
 
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient PresentationLosing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
 
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationCombination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
 
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek BaligaNewer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
 
Heart disease in post menopausal women
Heart disease in post menopausal womenHeart disease in post menopausal women
Heart disease in post menopausal women
 
Irritable Bowel Syndrome - Part 2
Irritable Bowel Syndrome - Part 2Irritable Bowel Syndrome - Part 2
Irritable Bowel Syndrome - Part 2
 
ECG In Ischemic Heart Disease - Dr Vivek Baliga Review
ECG In Ischemic Heart Disease - Dr Vivek Baliga ReviewECG In Ischemic Heart Disease - Dr Vivek Baliga Review
ECG In Ischemic Heart Disease - Dr Vivek Baliga Review
 
Understanding Enlarged Prostate Glands - Dr Vivek Baliga Patient Presentation
Understanding Enlarged Prostate Glands - Dr Vivek Baliga Patient PresentationUnderstanding Enlarged Prostate Glands - Dr Vivek Baliga Patient Presentation
Understanding Enlarged Prostate Glands - Dr Vivek Baliga Patient Presentation
 
Irritable Bowel Syndrome Part 1 - Dr Vivek Baliga
Irritable Bowel Syndrome Part 1 - Dr Vivek BaligaIrritable Bowel Syndrome Part 1 - Dr Vivek Baliga
Irritable Bowel Syndrome Part 1 - Dr Vivek Baliga
 
Post viral pericarditis - Dr Vivek Baliga presentation
Post viral pericarditis - Dr Vivek Baliga presentationPost viral pericarditis - Dr Vivek Baliga presentation
Post viral pericarditis - Dr Vivek Baliga presentation
 
Dr Vivek Baliga - Diastolic heart failure - A complete overview
Dr Vivek Baliga - Diastolic heart failure - A complete overviewDr Vivek Baliga - Diastolic heart failure - A complete overview
Dr Vivek Baliga - Diastolic heart failure - A complete overview
 
Dr Vivek Baliga - Chronic Disease Management In Heart Failure And Diabetes
Dr Vivek Baliga - Chronic Disease Management In Heart Failure And DiabetesDr Vivek Baliga - Chronic Disease Management In Heart Failure And Diabetes
Dr Vivek Baliga - Chronic Disease Management In Heart Failure And Diabetes
 
Pulmonary embolism - Diagnosis and management
Pulmonary embolism - Diagnosis and managementPulmonary embolism - Diagnosis and management
Pulmonary embolism - Diagnosis and management
 

Recently uploaded

Materials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxMaterials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxKAUSAR NAHID
 
SNORING AND OBSTRUCTIVE SLEEP APNEA.pdf ENT BY QUICKMEDTALK
SNORING AND OBSTRUCTIVE SLEEP APNEA.pdf ENT BY QUICKMEDTALKSNORING AND OBSTRUCTIVE SLEEP APNEA.pdf ENT BY QUICKMEDTALK
SNORING AND OBSTRUCTIVE SLEEP APNEA.pdf ENT BY QUICKMEDTALKQuick MedTalk
 
USE OF DRAINS IN SURGERY very good to have-1.pptx
USE OF DRAINS IN SURGERY very good to have-1.pptxUSE OF DRAINS IN SURGERY very good to have-1.pptx
USE OF DRAINS IN SURGERY very good to have-1.pptxKojoDanquah4
 
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEGINFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEGJuliethKabirigi1
 
Yantropakaranani 2: Heating Devices used in Ayurveda
Yantropakaranani 2: Heating Devices used in AyurvedaYantropakaranani 2: Heating Devices used in Ayurveda
Yantropakaranani 2: Heating Devices used in AyurvedaAparnaNandakumar12
 
Radicular cyst or periapical odontogenic cyst
Radicular cyst or periapical odontogenic cystRadicular cyst or periapical odontogenic cyst
Radicular cyst or periapical odontogenic cystJani253068
 
Shodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyShodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyAkshay Shetty
 
Fetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfFetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfMedicoseAcademics
 
RADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERRADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERKanhu Charan
 
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...bkling
 
Gallstones (Cholelithiasis) Lifestyle, Risk factors, preventions.pdf
Gallstones (Cholelithiasis) Lifestyle, Risk factors, preventions.pdfGallstones (Cholelithiasis) Lifestyle, Risk factors, preventions.pdf
Gallstones (Cholelithiasis) Lifestyle, Risk factors, preventions.pdfSudeb Ganguly
 
RASASHALA IN ACCORDANCE WITH GMP....pptx
RASASHALA IN ACCORDANCE WITH GMP....pptxRASASHALA IN ACCORDANCE WITH GMP....pptx
RASASHALA IN ACCORDANCE WITH GMP....pptxDr. Anusha Baseganni
 
Introduction to anatomy and physioligy.pptx
Introduction to anatomy and physioligy.pptxIntroduction to anatomy and physioligy.pptx
Introduction to anatomy and physioligy.pptxMarbahunJalaKharbhih
 
Sonostics - Preventing The Dementia Epidemic
Sonostics - Preventing The Dementia EpidemicSonostics - Preventing The Dementia Epidemic
Sonostics - Preventing The Dementia Epidemickjplace29
 
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...PeerVoice
 
Ways to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side EffectsWays to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side Effectsbkling
 
Vertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxVertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxYasser Alzainy
 

Recently uploaded (20)

Materials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxMaterials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptx
 
SNORING AND OBSTRUCTIVE SLEEP APNEA.pdf ENT BY QUICKMEDTALK
SNORING AND OBSTRUCTIVE SLEEP APNEA.pdf ENT BY QUICKMEDTALKSNORING AND OBSTRUCTIVE SLEEP APNEA.pdf ENT BY QUICKMEDTALK
SNORING AND OBSTRUCTIVE SLEEP APNEA.pdf ENT BY QUICKMEDTALK
 
USE OF DRAINS IN SURGERY very good to have-1.pptx
USE OF DRAINS IN SURGERY very good to have-1.pptxUSE OF DRAINS IN SURGERY very good to have-1.pptx
USE OF DRAINS IN SURGERY very good to have-1.pptx
 
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEGINFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
 
Yantropakaranani 2: Heating Devices used in Ayurveda
Yantropakaranani 2: Heating Devices used in AyurvedaYantropakaranani 2: Heating Devices used in Ayurveda
Yantropakaranani 2: Heating Devices used in Ayurveda
 
Radicular cyst or periapical odontogenic cyst
Radicular cyst or periapical odontogenic cystRadicular cyst or periapical odontogenic cyst
Radicular cyst or periapical odontogenic cyst
 
Shodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyShodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay Shetty
 
Pancreatic Cancer an Overview - CCSN 2024-02-29
Pancreatic Cancer an Overview - CCSN 2024-02-29Pancreatic Cancer an Overview - CCSN 2024-02-29
Pancreatic Cancer an Overview - CCSN 2024-02-29
 
Fetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfFetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdf
 
A case of Trichobezoar in a teenage female
A case of Trichobezoar in a teenage femaleA case of Trichobezoar in a teenage female
A case of Trichobezoar in a teenage female
 
A Comprehensive Fatty Liver Program .pptx
A Comprehensive Fatty Liver Program .pptxA Comprehensive Fatty Liver Program .pptx
A Comprehensive Fatty Liver Program .pptx
 
RADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERRADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCER
 
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
 
Gallstones (Cholelithiasis) Lifestyle, Risk factors, preventions.pdf
Gallstones (Cholelithiasis) Lifestyle, Risk factors, preventions.pdfGallstones (Cholelithiasis) Lifestyle, Risk factors, preventions.pdf
Gallstones (Cholelithiasis) Lifestyle, Risk factors, preventions.pdf
 
RASASHALA IN ACCORDANCE WITH GMP....pptx
RASASHALA IN ACCORDANCE WITH GMP....pptxRASASHALA IN ACCORDANCE WITH GMP....pptx
RASASHALA IN ACCORDANCE WITH GMP....pptx
 
Introduction to anatomy and physioligy.pptx
Introduction to anatomy and physioligy.pptxIntroduction to anatomy and physioligy.pptx
Introduction to anatomy and physioligy.pptx
 
Sonostics - Preventing The Dementia Epidemic
Sonostics - Preventing The Dementia EpidemicSonostics - Preventing The Dementia Epidemic
Sonostics - Preventing The Dementia Epidemic
 
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
 
Ways to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side EffectsWays to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side Effects
 
Vertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxVertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptx
 

Atorvastatin:  Statins in CVD management. Is just lipid lowering enough

  • 1. Statins in CVD management : Is just lipid lowering enough? Dr Vivek Baliga Consultant Internal Medicine Director, HeartSenseTM www.heartsense.in
  • 2. Preamble • Statins were originally introduced as lipid lowering drugs, but today they are recommended in many high risk patient groups irrespective of baseline lipid levels. • This suggests that benefits of statins are beyond and independent of lipid lowering effects. • So Choice of statin should be based on evidence of CV benefits rather than lipid lowering
  • 3. Primary Prevention of CVD • As per AHA 2013, guidelines all T2DM patients of age 40-75 require either moderate or high dose statin therapy
  • 4. 2016 ADA guidelines for statins in DM Diabetes Care 2016;39(supple 1): S1-S112
  • 5. All DM patients with> 1 CV risk factor require moderate to high dose statin But what is the evidence that statins reduce CV events in T2DM patients without high LDL-C?
  • 6. MI Risk in Diabetics Without Prior MI Equivalent to Nondiabetic With MI Haffner SM et al. N Engl J Med. 1998;339:229-234. Numbers in bars represent number of persons in category at baseline. Finnish population study (7-year follow-up) 3.5 20.218.8 45 0 10 20 30 40 50 60 Patients without diabetes Patients with diabetes Incidenceoffatal/nonfatalMI during7-yearfollow-up(%) No prior MI Prior MI P<0.001 P<0.001 P<0.001 for diabetes vs no diabetes 8901304 69 169
  • 7. Diabetes is CHD equivalent
  • 8. RM Parikh et al. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 4 (2010) 10–12 85.5% Dyslipidemia 97.8 % Dyslipidemia 85.5 % Prevalence of Dyslipidemia (%) in Male T2 DM Prevalence of Dyslipidemia (%) in Female T2DM In India, 90% diabetics have dyslipidemia
  • 9. Study Patients Follow up Results ASCOT LLA * 2532 Atorvastatin 10 mg 3.3 yrs 23% risk reduction CARDS 2838 Atorvastatin 10 mg 3.9 yrs 37% risk reduction HPS * 2912 Simvastatin 40 mg 5 yrs 33% risk reduction Major Statin Primary Prevention Trials In DM * sub-analysis Only Atorvastatin and Simvastatin have evidence that statin reduce CV events in Primary prevention. OTHERS DO NOT HAVE SUCH EVIDENCE!
  • 10. 4-year follow-up CARDS: primary prevention in T2DM Atorvastatin 10 mg/day (n=1428) Placebo (n=1410) 2838 patients Primary end point:  Incidence of major cardiovascular events: – Cardiovascular-related death – Nonfatal MI – Stroke – Resuscitated cardiac arrest – Unstable angina – Coronary revascularization procedures Patient population:  Age: 40-75 years  LDL-C 160 mg/dL  Triglycerides 600 mg/dL  Type 2 diabetes  No prior MI or CHD  1+ CHD risk factor C o l h o u n H M e t a l . L a n c e t . 2 0 0 4 ; 3 6 4 : 6 8 5 - 6 9 6 . CARDS: Collaborative Atorvastatin Diabetes Study At Baseline, LDL-C: 120 mg/dl HDL-C: 54.5 mg/dl Non-HDL-C: 153 mg/dl
  • 11. CARDS: Atorvastatin reduces CV events by 37% *Acute CHD event, coronary revascularization, stroke. RRR: Relative risk reduction Colhoun HM et al. Lancet. 2004;364:685-696. 0 5 10 15 0 1 2 3 4 5 6 RRR=37% p=0.001 Cumulativeincidence ofevents(%ofpatients) 127 events 83 events Time (years) Atorvastatin 10 mg (n=1428) Placebo (n=1410) median follow-up 3.9 years
  • 12. 0 1 2 3 4 5 6 0 1 2 3 4 5 6 CARDS: Atorvastatin Reduces Stroke by 48% in T2DM Newman C et al. American Heart Association 78th Scientific Sessions, 2005. RRR= 48% (95% CI: 31%-89%) P=0.016 Cumulativeincidence ofevents(%ofpatients) 39 events 21 events Time (years) Atorvastatin 10 mg (n=1428) Placebo (n=1410) Median follow-up 3.9 years Stroke was a component of the primary endpoint, evaluated individually as a secondary survival analysis.
  • 13. AHA and ADA guidelines for statin therapy in T2DM for primary prevention are based on Atorvastatin’s CARDS trial
  • 14. Atorvastatin for Primary Prevention in High risk patients: ASCOT-LLA A double-blind, placebo-controlled trial of atorvastatin 10 mg Vs Placebo in 10305 hypertensive patients studied Median follow up: 3.3 years Study end points Primary: Combined nonfatal MI (including silent MI) and fatal CHD Secondary: Fatal and nonfatal stroke Total cardiovascular events and procedures Total coronary events
  • 15. Atorvastatin 10 mg Number of events 89 Placebo Number of events 121 0 1 2 3 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 Years CumulativeIncidence(%) HR = 0.73 (0.56-0.96) P = .0236 27% reduction ASCOT-LLA Primary Endpoint: Nonfatal MI and Fatal CHD Secondary Endpoint: Fatal and Nonfatal Stroke 0 1 2 3 4 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 Years CumulativeIncidence(%) Atorvastatin 10 mg Number of events 100 Placebo Number of events 154 36% reduction HR = 0.64 (0.50-0.83) P = .0005 Sever PS, et al. Lancet. 2003;361:1149-1158.
  • 16. ASCOT-LLA: Primary prevention– DM Sub- analysis (yellow cells) Highlighted boxes indicate diabetes patients enrolled in lipid-lowering arm. -blocker ± diuretic CCB ± ACE inhibitor TC >250 mg/dL (>6.5 mmol/L) 2532 TC 250 mg/dL (6.5 mmol/L) TC >250 mg/dL (>6.5 mmol/L) Open lipid lowering 1258 Atorvastatin 10 mg 1274 Placebo Open lipid lowering 19,342 patients Randomized Randomized Primary end point: Composite of fatal CHD and nonfatal MI ASCOT: LLA: Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm Sever PS et al. J Hypertens. 2001;19:1139-1147. CCB: Calcium Channel Blocker ACE: Angiotension Convertase Inhibitor TC: Total Cholesterol
  • 17. ASCOT-LLA :23% RRR for total CV events in DM patients with atorvastatin Sever PS et al. Diabetes Care. 2005;28:1151-1157. 0 5 10 15 0 1 2 3 4 5 6 RRR=23% P=0.036 151 events 116 events median follow-up 3.3 years Cumulativeincidence ofevents(%ofpatients) Time (years) Atorvastatin 10 mg Placebo
  • 18. Statin in CKD patients Alterations in Lipid Profiles in CKD Clin J Am Soc Nephrol 2007; 2(4):766-85. Triglycerides HDL Lipoprotein (a) Normal or low LDL Normal or low TC VLDL remnants
  • 19. Dose of statins in patients with CKD • Atorvastatin: No dose adjustment required • Rosuvastatin: In patients severe CKD with creatinine clearance < 30 ml/min (not on hemodialysis), Maximum dose: 10 mg/day • Pitavastatin: in patients with moderate/severe CKD (GFR: 15-59 ml/min) Maximum dose: 2 mg/day, GFR: Glomerular Filtration Rate
  • 20. • Patients: 325 DM nephropathy patients urinary protein/creatinine ratios (UPCR): 500-5000 mg/g, LDL >90 mg/dL, and on ACEIs/ARBs for > 3 months. • Patients divided in 3 groups: Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg for duration of 52 weeks • Baseline eGFR: 69-72 ml/min Baseline UPCR: 1160-1260 mg/g • The primary end point: Change in urinary protein/ creatinine ratio from baseline to week 52 Atorvastatin vs Rosuvastatin in DM+ CKD PLANET I study The Lancet Diabetes & Endocrinology 2015;3(3):181-90
  • 21. PLANET I: % Change in UPCR and eGFR -13 2 -4 -14 -12 -10 -8 -6 -4 -2 0 2 4 UPCR Change (%) Atorvastatin 80 mg Rosuvastatin 10 mg Rosuvastatin 40 mg p=0.033 p=0.83 p=0.53 The Lancet Diabetes & Endocrinology 2015;3(3):181-90 -1.61 -3.7 -7.29 -8 -7 -6 -5 -4 -3 -2 -1 0 Change in eGFR Atorvastatin 80 mg Rosuvastatin 10 mg Rosuvastatin 40 mg Conclusion: Atorvastatin seems to have more renoprotective effects for the studied chronic kidney disease population.
  • 22. de Zeeuw D. 2010European Renal Association-European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany. Atorvastatin vs Rosuvastatin for renal function PLANET I: Adverse event Rosuvastatin 10 mg/day (n = 116) Rosuvastatin 40 mg/day (n = 123) Atorvastatin 80 mg/day (n = 110) p Any renal adverse event 7.8 9.8 4.5 NS Acute renal failure 0.0 4.1 0.9 <0.05 Serum creatinine doubling 0.0 4.9 0.0 <0.01 Serum creatinine doubling or acute renal failure 0.0 7.3 0.9 <0.01
  • 23. • A meta-analysis of 5 clinical trials head to head comparing atorvastatin vs rosuvastatin Atorvastatin Vs Rosuvastatin For Proteinuria: A Meta-analysis Circ J 2012;76:1259-66
  • 24. Atorvastatin is safer than Rosuvastatin in DM patients with proteinuria Atorvastatin is better than Rosuvastatin for reduction in proteinuria
  • 25. 2013 KDIGO Guidelines for dyslipidemia management in CKD • In adults aged > 50 years with eGFR< 60 ml/min/1.73 m2 but not treated with chronic dialysis or kidney transplantation (GFR categories G3a-G5), we recommend treatment with a statin or statin/ezetimibe combination. (1A) • In adults aged > 50 years with CKD and eGFR> 60 ml/min/1.73m2 (GFR categories G1-G2) we recommend treatment with a statin. (1B)
  • 26. Rosuvastatin 20 mg (N=8901) MI Stroke Unstable Angina CVD Death CABG/PTCA 4-week run-in Ridker PM et al, Circulation 2003;108:2292-2297 No Prior CVD/CKD/DM Men >50, Women >60 LDL <130 mg/dL hsCRP >2 mg/L Placebo (N=8901) Follow up: 1.9 yrs Can we consider rosuvastatin for primary prevention in DM/CKD based on JUPITER? Patients with DM and CKD were excluded from JUPITER, So there is no evidence for primary CV prevention with rosuvastatin in DM/CKD!!!
  • 27. Statin for secondary prevention • Current guidelines recommend moderate to high dose of statins for secondary prevention. • Atorvastatin has multiple landmark trials for secondary prevention
  • 28. 771 pts with NSTE-ACS sent to early coronary angiography (<48 hours) Randomization(N=191) Atorvastatin 80 mg 12 hrs pre-angio; further 40 mg 2 hrs before N=96 Coronary angiography Placebo 12 hrs pre-angio; further dose 2 hrs before N=95 Primary end point: 30-day death, MI, TVR 1st blood sample (pre-PCI) CK-MB, troponin-I, myoglobin, CRP High dose Atorvastatin in ACS ARMYDA-ACS trial 2nd and 3rd blood samples (8 and 24 hrs post-PCI) 30 days 580 pts excluded for: - 451 statin therapy - 41 emergency angiography - 43 LVEF <30% - 30 contraindications to statins - 15 severe renal failure PCI atorvastatin N=86 PCI placebo N=85 20 pts excluded for indication to: - medical therapy (N=8) - bypass surgery (N=12) atorvast
  • 29. ARMYDA-ACS: Secondary end point Post-PCI percent increase of CRP levels from baseline % 63 147 P=0.01 JACC 2007:49:1272-78
  • 30. ARMYDA-ACS trial Composite primary end-point (30-day death, MI, TVR) % 5 17 P=0.01 JACC 2007:49:1272-78
  • 31. • 383 patients with stable angina (53%) or NST-ACS (47%) and on chronic statin therapy (55% atorvastatin) undergoing PCI were randomized to atorvastatin reload (80 mg 12 h before intervention, 40-mg pre-procedural dose or placebo (n=191). • All patients received long-term atorvastatin treatment thereafter (40 mg/day). • The primary end point was 30-day incidence of major adverse cardiac events (cardiac death, myocardial infarction, or unplanned revascularization). Loading atorvastatin in patients already on statin ARMYDA-RECAPTURE J. Am. Coll. Cardiol. 2009;54;558-565
  • 32. ARMYDA-RECAPTURE: PRIMARY ENDPOINT 0 3 6 9 12 3.4 9.1 P=0.045 PlaceboAtorvastatin Loading of Atorvastatin high dose before PCI can reduce the CV events J. Am. Coll. Cardiol. 2009;54;558-565
  • 33. Atorvastatin 80 mg n=4,995 Primary Endpoint: Major cardiovascular event defined as coronary heart death (CHD), nonfatal M, resuscitated cardiac arrest, and fatal or nonfatal stroke at a mean follow-up of 4.9 years. Atorvastatin for stable CAD TNT Trial Presented at ACC 2005 Atorvastatin 10 mg n=5,006 10,003 patients with stable coronary heart disease Age 35-75 years, LDL between 130 and 250 mg/dL, triglyceride ≤ 600 mg/dL 19% female, mean age 60.3 years All received atorvastatin 10 mg during 8 week open-label run-in period
  • 34. TNT Trial: Primary endpoint Hazard Ratio [HR]=0.78 p<0.001 Presented at ACC 2005
  • 35. 4,162 patients with an Acute Coronary Syndrome < 10 days ASA + Standard Medical Therapy “Standard Therapy” Pravastatin 40 mg “Intensive Therapy” Atorvastatin 80 mg Duration: Mean 2 year follow-up (>925 events) Atorvastatin in ACS: PROVE IT - TIMI 22 2x2 Factorial: Gatifloxacin vs. placebo Double-blind Primary Endpoint: Death, MI, Documented UA requiring hospitalization, revascularization (> 30 days after randomization), or Stroke
  • 36. CV events in PROVE IT study Cannon et al. NEJM 2004 Ray et al. Am J Cardiol 2006 Death/MACEDeath/MI/Urg. Revascu. ↓33% ↓16% Intensive statin therapy provides more benefits than low/moderate Intensity statin
  • 37. Take Home Message • CV protection with statin is not completely dependent on lipid lowering. • Though rosuvastatin is slightly more effective than atorvastatin for lipid lowering, Atorvastatin has stronger evidence for CV protection • Atorvastatin is approved in both primary and secondary prevention, while rosuvastatin is approved only in primary prevention in patients with hsCRP > 2 mg/L WITHOUT DM/CKD